In this video, Motley Fool health-care bureau chief Brenton Flynn takes a look through some recent SEC filings where investors don't often look for information, to discover some of the less-reported information on some of the biggest names in the health-care investments sector today. He discusses Abbott Labs (NYSE: ABT) and its coming spinoff AbbVie, a new indication for Questcor (NASDAQ: QCOR), a savvy sell by Dendreon (NASDAQ: DNDN), general pessimism about the economic climate from Express Scripts (NASDAQ: ESRX), and some uncertainty from MAKO Surgical (NASDAQ:MAKO) in the wake of Hurricane Sandy.
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Motley Fool analyst Brenton Flynn pours through some recent SEC filings to uncover some interesting info-nuggets.
Brenton Flynn and Max Macaluso have no positions in the stocks mentioned above. The Motley Fool owns shares of Dendreon, Express Scripts, and MAKO Surgical. Motley Fool newsletter services recommend Express Scripts and MAKO Surgical. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Invest Smarter with The Motley Fool
Join Over Half a Million Premium Members Receiving…
- New Stock Picks Each Month
- Detailed Analysis of Companies
- Model Portfolios
- Live Streaming During Market Hours
- And Much More
Motley Fool Investing Philosophy
- #1 Buy 25+ Companies
- #2 Hold Stocks for 5+ Years
- #3 Add New Savings Regularly
- #4 Hold Through Market Volatility
- #5 Let Winners Run
- #6 Target Long-Term Returns
Why do we invest this way? Learn More
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.